Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inspire Pharmaceuticals, a biopharmaceutical company, has announced that the US Patent and Trademark Office has issued a method of treatment patent related to Elestat 0.05% for allergic conjunctivitis.
Subscribe to our email newsletter
This patent was issued to Boehringer Ingelheim International, the developer of the invention, and expires on November 29, 2020.
Elestat, a topical antihistamine with mast cell stabilizing and anti-inflammatory activity, is licensed from Boehringer Ingelheim and was developed by Allergan, for the relief of ocular itching associated with ocular allergies.
Following the approval of the drug in 2003, Allergan entered into a co-promotion agreement with Inspire pursuant to which Inspire obtained the primary responsibility for selling, promotional and marketing activities in the US related to Elestat.
Christy Shaffer, president and CEO of Inspire, said: “As Elestat is an important product for Inspire, we are pleased to have patent coverage for Elestat that extends beyond the exclusivity period granted under the Hatch-Waxman Act. We look forward to continuing our promotion of Elestat.”